Royalty Pharma plc Amortization of Intangible Assets
Royalty Pharma plc (RPRX) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2025-02-12
- Royalty Pharma plc amortization of intangible assets for the quarter ending 2023-12-31 was $0.00.
- Royalty Pharma plc amortization of intangible assets for the quarter ending 2023-09-30 was $0.00.
- Royalty Pharma plc amortization of intangible assets for the quarter ending 2023-06-30 was $0.00.
- Royalty Pharma plc amortization of intangible assets for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc amortization of intangible assets for fiscal 2024 was $0.00.
- Royalty Pharma plc amortization of intangible assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Royalty Pharma plc amortization of intangible assets for fiscal 2022 was $5.67M, a 75.34% decline from fiscal 2021.
- Royalty Pharma plc amortization of intangible assets for fiscal 2021 was $23.00M, a 0.27% decline from fiscal 2020.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $5.67M 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $5.67M 10-Q · filed 2023-11-08 | $11.47M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $5.67M 10-Q · filed 2023-08-08 | $11.47M derived: sum of 3 quarters · filed 2024-02-15 | $17.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $5.67M 10-Q · filed 2023-05-09 | $11.47M derived: sum of 2 quarters · filed 2024-02-15 | $17.26M derived: sum of 3 quarters · filed 2024-02-15 | $23.00M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $11.59M derived: sum of 2 quarters · filed 2024-02-15 | $17.32M derived: sum of 3 quarters · filed 2024-02-15 | $23.00M 10-K · filed 2024-02-15 |
| 2021-09-30 | $5.80M 10-Q · filed 2022-11-08 | $11.53M derived: sum of 2 quarters · filed 2022-11-08 | $17.20M 10-Q · filed 2022-11-08 | $23.00M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $5.73M 10-Q · filed 2022-08-04 | $11.40M 10-Q · filed 2022-08-04 | $17.20M derived: sum of 3 quarters · filed 2023-02-15 | $23.00M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $5.67M 10-Q · filed 2022-05-05 | $11.47M derived: sum of 2 quarters · filed 2023-02-15 | $17.26M derived: sum of 3 quarters · filed 2023-02-15 | $23.00M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $11.59M derived: sum of 2 quarters · filed 2023-02-15 | $17.32M derived: sum of 3 quarters · filed 2023-02-15 | $23.06M 10-K · filed 2023-02-15 |
| 2020-09-30 | $5.80M 10-Q · filed 2021-11-10 | $11.53M derived: sum of 2 quarters · filed 2021-11-10 | $17.26M 10-Q · filed 2021-11-10 | $23.06M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $5.73M 10-Q · filed 2021-08-11 | $11.47M 10-Q · filed 2021-08-11 | $17.26M derived: sum of 3 quarters · filed 2022-02-15 | $23.06M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $5.73M 10-Q · filed 2021-05-11 | $11.53M derived: sum of 2 quarters · filed 2022-02-15 | $17.32M derived: sum of 3 quarters · filed 2022-02-15 | $23.06M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $11.59M derived: sum of 2 quarters · filed 2022-02-15 | $17.32M derived: sum of 3 quarters · filed 2022-02-15 | $23.92M 10-K · filed 2022-02-15 |
| 2019-09-30 | $5.80M 10-Q · filed 2020-11-12 | $11.53M derived: sum of 2 quarters · filed 2020-11-12 | $18.13M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $5.73M 10-Q · filed 2020-08-12 | $12.33M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $33.27M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |